Delivery on demand - A new era of gene therapy?

New England Journal of Medicine

Volumn 348, Issue 13, 2003, Pages 1282-1283

  Prchal, Josef T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; HYPOXIA INDUCIBLE FACTOR 1; RECOMBINANT ERYTHROPOIETIN;

ANGIOGENESIS; ARTICLE; BETA THALASSEMIA; CANCER SUSCEPTIBILITY; DRUG COST; EMBRYO DEVELOPMENT; ENERGY METABOLISM; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC CODE; GENETIC DISORDER; HEMOPHILIA; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SICKLE CELL ANEMIA;

ANEMIA; ANIMALS; ANOXIA; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; GENE THERAPY; MICE;

EID: 0037468676     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcibr035011     Document Type: Article

References (4)

1. Binley K, Askham Z, Iqball S, et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002;100:2406-13.
2. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001;107:1-3.
3. Zhu H, Bunn HF. Signal transduction: how do cells sense oxygen? Science 2001;292:449-51.
4. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614-21.